Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796100 | 1.00 | BACE1 (0.33) | BACE1CYP3A4ALDH1A1 | |
| SCHEMBL18149538 | 0.80 | CYP3A4 (0.37) | BACE1CYP3A4ALDH1A1 | |
| SCHEMBL23213595 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL17094641 | 0.76 | BACE1 (0.33) | BACE1 | |
| SCHEMBL13303926 | 0.76 | ALDH1A1 (0.33) | BACE1CYP3A4ALDH1A1 | |
| SCHEMBL23213525 | 0.75 | CASR (0.36) | BACE1ALDH1A1 | |
| SCHEMBL21395337 | 0.74 | BACE1 (0.33) | BACE1 | |
| SCHEMBL21163340 | 0.73 | ALDH1A1 (0.39) | BACE1CYP3A4ALDH1A1 | |
| SCHEMBL23581038 | 0.73 | TDP1 (0.35) | ALDH1A1 | |
| SCHEMBL29882588 | 0.73 | TDP1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | BACE1 3674/4885CYP3A4 3128/4885ALDH1A1 4150/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | BACE1 3274/4885CYP3A4 463/4885ALDH1A1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.